Flerobuterol (INNTooltip International Nonproprietary Name; developmental code name CRL-40827) is a selective β-adrenergic receptor agonist related to salbutamol which was under development for the treatment of major depressive disorder but was never marketed.[1][2][3] It is an agonist of the β1-, β2-, and β3-adrenergic receptors.[2][4] The drug was under development in France by Cephalon and Lafon and reached phase 2 clinical trials prior to its development being discontinued.[1] It was first described in the scientific literature by 1988[3] and its development was terminated in 2007.[1]

References

  1. ^ a b c "Flerobuterol". AdisInsight. Springer Nature Switzerland AG. 26 October 2011. Retrieved 27 September 2024.
  2. ^ a b Bosker FJ, Westerink BH, Cremers TI, Gerrits M, van der Hart MG, Kuipers SD, et al. (2004). "Future antidepressants: what is in the pipeline and what is missing?". CNS Drugs. 18 (11): 705–732. doi:10.2165/00023210-200418110-00002. PMID 15330686.
  3. ^ a b Chariot J, De La Tour J, Vaille C, Rozé C (January 1988). "Effects of CRL 40827 and salbutamol on exocrine pancreatic secretion in rats". European Journal of Pharmacology. 146 (1): 17–25. doi:10.1016/0014-2999(88)90482-7. PMID 2895009.
  4. ^ Zini R, Morin D, Martin P, Puech AJ, Tillement JP (October 1991). "Interactions of flerobuterol, an antidepressant drug candidate, with beta adrenoceptors in the rat brain". The Journal of Pharmacology and Experimental Therapeutics. 259 (1): 414–422. PMID 1681091.
Allikas: http://en.wikipedia.org/wiki/Flerobuterol
No tags for this post.